Polyclonal and monoclonal antibodies in clinic

Methods in Molecular Biology

Volumn 1060, Issue , 2014, Pages 79-110

  Wootla, Bharath ^a   Denic, Aleksandar ^a   Rodriguez, Moses ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antibody; Disorders; Monoclonal antibodies; Polyclonal antibodies

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CANAKINUMAB; CERTOLIZUMAB PEGOL; CETUXIMAB; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; GEMTUZUMAB; GOLIMUMAB; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; OFATUMUMAB; OKT 3; OMALIZUMAB; ORTHOCLONE OKT 3; PANITUMUMAB; POLYCLONAL ANTIBODY; RANIBIZUMAB; RITUXIMAB; TOCILIZUMAB; TOSITUMOMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; FC RECEPTOR; IMMUNOGLOBULIN G;

ACUTE GRANULOCYTIC LEUKEMIA; ALLERGIC ASTHMA; ANAPHYLAXIS; ANKYLOSING SPONDYLITIS; ANTIBODY ISOLATION; ANTIBODY PRODUCTION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; B LYMPHOCYTE; BACKACHE; BRAIN INFECTION; BREAST CANCER; CANCER IMMUNOTHERAPY; CARDIOVASCULAR DISEASE; CELL CLONE; CHRONIC LYMPHATIC LEUKEMIA; CHURG STRAUSS SYNDROME; CINCA SYNDROME; COLORECTAL CANCER; COMMON VARIABLE IMMUNODEFICIENCY; CROHN DISEASE; DENDRITIC CELL; DERMATOMYOSITIS; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG SYNTHESIS; DRUG WITHDRAWAL; EATON LAMBERT SYNDROME; EXUDATIVE MACULAR DEGENERATION; FLU LIKE SYNDROME; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GUILLAIN BARRE SYNDROME; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMOLYSIS; HODGKIN DISEASE; HUMAN; HYPERTENSION; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; JUVENILE RHEUMATOID ARTHRITIS; LEG PAIN; LOW DRUG DOSE; MACROPHAGE; MONOCYTE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYCOSIS; NONHODGKIN LYMPHOMA; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMYOSITIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RETINA MACULA DEGENERATION; RHEUMATOID ARTHRITIS; RIGOR; SEPSIS; SEVERE COMBINED IMMUNODEFICIENCY; STIFF MAN SYNDROME; SUPPURATIVE HIDRADENITIS; THROMBOEMBOLISM; VIRUS MENINGITIS; VISUAL IMPAIRMENT; WISKOTT ALDRICH SYNDROME; ACUTE MYELOBLASTIC LEUKEMIA; ADVERSE OUTCOME; BONE METASTASIS; DRUG EFFECT; GRANULOCYTE; HISTORY; HOSPITAL; IMMUNOGLOBULIN PRODUCTION; IMMUNOTHERAPY; INFLAMMATION; LUPUS VULGARIS; MACULAR DEGENERATION; MELANOMA; META ANALYSIS (TOPIC); NATURAL KILLER CELL; PHASE 2 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; PRODUCT SAFETY; REGENERATION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS;

EID: 84931271058     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-586-6_5     Document Type: Article

References (225)

1. Behring E, Kitasato S (1890) Ueber das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren. Dtsch Med Wochenschr 16:1113-1
2. Hallauer C (1954) Emil von Behring, the man and his work. Schweiz Z Pathol Bakteriol 17:392-3
3. Bochalli R (1956) Alfred Nobel and the German Nobel prize winners for physiology and medicine. Med Monatsschr 10:44-4
4. Lejeune F (1951) German Nobel Prize winners. Med Welt 20:429-4
5. Nicolle C, Conseil E (1918) Pouvoir préventif du sérum d'un malade convalescent de rougeole. Bull Mem Soc Med Hop Paris 42:3
6. Degkwitz R (1920) Über Versuche mit Masernrekonvaleszentenserum. Ztschr f Kinderh 25:1
7. Rezaei N, Abolhassani H, Aghamohammadi A, Ochs HD (2011) Indications and safety of intravenous and subcutaneous immunoglobulin therapy. Expert Rev Clin Immunol 7:301-3
8. Mc KC (1937) The prevention and modification of measles. JAMA 109:2034-2
9. Eibl MM (2008) History of immunoglobulin replacement. Immunol Allergy Clin North Am 28:737-764, viii
10. Bruton OC (1952) Agammaglobulinemia. Pediatrics 9:722-728
11. Barandun S, Kistler P, Jeunet F, Isliker H (1962) Intravenous administration of human gamma-globulin. Vox Sang 7:157-174
12. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, Buckley R, Chinen J, El-Gamal Y, Mazer BD, Nelson RP Jr, Patel DD, Secord E, Sorensen RU, Wasserman RL, Cunningham-Rundles C (2006) Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 117:S525-S553
13. Avrameas S (1991) Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol Today 12:154-159
14. Lacroix-Desmazes S, Mouthon L, Coutinho A, Kazatchkine MD (1995) Analysis of the natural human IgG antibody repertoire: lifelong stability of reactivities towards self antigens contrasts with age-dependent diversification of reactivities against bacterial antigens. Eur J Immunol 25:2598-2604
15. Mouthon L, Haury M, Lacroix-Desmazes S, Barreau C, Coutinho A, Kazatchkine MD (1995) Analysis of the normal human IgG antibody repertoire. Evidence that IgG autoantibodies of healthy adults recognize a limited and conserved set of protein antigens in homologous tissues. J Immunol 154: 5769-5778
16. Nobrega A, Haury M, Grandien A, Malanchere E, Sundblad A, Coutinho A (1993) Global analysis of antibody repertoires. II. Evidence for specificity, self- selection and the immunological "homunculus" of antibodies in normal serum. Eur J Immunol 23:2851-2859
17. Varela F, Andersson A, Dietrich G, Sundblad A, Holmberg D, Kazatchkine M, Coutinho A (1991) Population dynamics of natural antibodies in normal and autoimmune individuals. Proc Natl Acad Sci U S A 88:5917-5921
18. Varela FJ, Coutinho A (1991) Second generation immune networks. Immunol Today 12:159-166
19. Gelfand EW (2006) Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol 6:592-599
20. Lam L, Whitsett CF, McNicholl JM, Hodge TW, Hooper J (1993) Immunologically active proteins in intravenous immunoglobulin. Lancet 342:678
21. Blasczyk R, Westhoff U, Grosse-Wilde H (1993) Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 341:789-790
22. Bayry J, Negi VS, Kaveri SV (2011) Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol 7: 349-359
23. Buchacher A, Iberer G (2006) Purification of intravenous immunoglobulin G from human plasma-aspects of yield and virus safety. Biotechnol J 1:148-163
24. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schoni M, Vest M, Wagner HP (1981) Highdose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1:1228-1231
25. Fehr J, Hofmann V, Kappeler U (1982) Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 306:1254-1258
26. Notarangelo LD (2010) Primary immunodeficiencies. J Allergy Clin Immunol 125: S182-S194
27. Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345: 747-755
28. Tha-In T, Bayry J, Metselaar HJ, Kaveri SV, Kwekkeboom J (2008) Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 29:608-615
29. Luke PP, Scantlebury VP, Jordan ML, Vivas CA, Hakala TR, Jain A, Somani A, Fedorek S, Randhawa P, Shapiro R (2001) Reversal of steroid- and anti-lymphocyte antibody- resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation 72:419-422
30. Sokos DR, Berger M, Lazarus HM (2002) Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 8:117-130
31. Casadei DH, del CRM, Opelz G, Golberg JC, Argento JA, Greco G, Guardia OE, Haas E, Raimondi EH (2001) A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 71:53-58
32. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders SP et al (1986) The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315:341-347
33. Silverman ED, Somma C, Khan MM, Melmon KL, Engleman EG (1990) Abnormal T suppressor cell function in juvenile rheumatoid arthritis. Arthritis Rheum 33:205-211
34. Kaneko Y, Nimmerjahn F, Ravetch JV (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313:670-673
35. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV (2008) Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320:373-376
36. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV (2011) Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 475:110-113
37. Kasermann F, Boerema DJ, Ruegsegger M, Hofmann A, Wymann S, Zuercher AW, Miescher S (2012) Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation. PLoS One 7:e37243
38. Basta M, Dalakas MC (1994) High-dose intravenous immunoglobulin exerts its benefi- cial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 94: 1729-1735
39. Basta M, Langlois PF, Marques M, Frank MM, Fries LF (1989) High-dose intravenous immunoglobulin modifies complement- mediated in vivo clearance. Blood 74:326-333
40. Basta M, Kirshbom P, Frank MM, Fries LF (1989) Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 84:1974-1981
41. Sato M, Kojima H, Koshikawa S (1986) Modification of immune complexes deposited in glomeruli in tissue sections treated with sulfonized gamma-globulin. Clin Exp Immunol 64:623-628
42. Lin CY, Hsu HC, Chiang H (1989) Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin. Nephron 53:303-310
43. Leung DY, Cotran RS, Kurt-Jones E, Burns JC, Newburger JW, Pober JS (1989) Endothelial cell activation and high interleukin- 1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 2:1298-1302
44. Aukrust P, Froland SS, Liabakk NB, Muller F, Nordoy I, Haug C, Espevik T (1994) Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 84:2136-2143
45. Sharief MK, Ingram DA, Swash M, Thompson EJ (1999) I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain- Barre syndrome. Neurology 52:1833-1838
46. Xu C, Poirier B, Duong Van Huyen JP, Lucchiari N, Michel O, Chevalier J, Kaveri S (1998) Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseases. Am J Pathol 153:1257-1266
47. Leung DY (1996) Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin. Clin Exp Immunol 104(Suppl 1):49-54
48. Ashkenazi S, Cleary TG, Lopez E, Pickering LK (1988) Anticytotoxin- neutralizing antibodies in immune globulin preparations: potential use in hemolytic-uremic syndrome. J Pediatr 113:1008-1014
49. Leung DY, Kelly CP, Boguniewicz M, Pothoulakis C, LaMont JT, Flores A (1991) Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 118:633-637
50. Abe J, Jibiki T, Noma S, Nakajima T, Saito H, Terai M (2005) Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. J Immunol 174:5837-5845
51. Rhoades CJ, Williams MA, Kelsey SM, Newland AC (2000) Monocyte-macrophage system as targets for immunomodulation by intravenous immunoglobulin. Blood Rev 14:14-30
52. Kimberly RP, Salmon JE, Bussel JB, Crow MK, Hilgartner MW (1984) Modulation of mononuclear phagocyte function by intravenous gamma-globulin. J Immunol 132: 745-750
53. Salama A, Mueller-Eckhardt C, Kiefel V (1983) Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet 2: 193-195
54. Bussel JB, Kimberly RP, Inman RD, Schulman I, Cunningham-Rundles C, Cheung N, Smithwick EM, O'Malley J, Barandun S, Hilgartner MW (1983) Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood 62: 480-486
55. Debre M, Bonnet MC, Fridman WH, Carosella E, Philippe N, Reinert P, Vilmer E, Kaplan C, Teillaud JL, Griscelli C (1993) Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 342:945-949
56. Kaneko Y, Nimmerjahn F, Madaio MP, Ravetch JV (2006) Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 203:789-797
57. van Mirre E, Teeling JL, van der Meer JW, Bleeker WK, Hack CE (2004) Monomeric IgG in intravenous Ig preparations is a functional antagonist of FcgammaRII and FcgammaRIIIb. J Immunol 173:332-339
58. von Gunten S, Schaub A, Vogel M, Stadler BM, Miescher S, Simon HU (2006) Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood 108: 4255-4259
59. Chang J, Shi PA, Chiang EY, Frenette PS (2008) Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. Blood 111:915-923
60. Jarius S, Eichhorn P, Albert MH, Wagenpfeil S, Wick M, Belohradsky BH, Hohlfeld R, Jenne DE, Voltz R (2007) Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNFalpha-dependent and Fc-receptorindependent way. Blood 109:4376-4382
61. Kwak JY, Kwak FM, Ainbinder SW, Ruiz AM, Beer AE (1996) Elevated peripheral blood natural killer cells are effectively downregulated by immunoglobulin G infusion in women with recurrent spontaneous abortions. Am J Reprod Immunol 35:363-369
62. Daya S, Gunby J, Clark DA (1998) Intravenous immunoglobulin therapy for recurrent spontaneous abortion: a metaanalysis. Am J Reprod Immunol 39:69-76
63. Hutton B, Sharma R, Fergusson D, Tinmouth A, Hebert P, Jamieson J, Walker M (2007) Use of intravenous immunoglobulin for treatment of recurrent miscarriage: a systematic review. BJOG 114:134-142
64. Finberg RW, Newburger JW, Mikati MA, Heller AH, Burns JC (1992) Effect of high doses of intravenously administered immune globulin on natural killer cell activity in peripheral blood. J Pediatr 120:376-380
65. Tha-In T, Metselaar HJ, Tilanus HW, Groothuismink ZM, Kuipers EJ, de Man RA, Kwekkeboom J (2007) Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cells. Blood 110:3253-3262
66. Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, Chevailler A, Mouthon L, Weill B, Bruneval P, Kazatchkine MD, Kaveri SV (2003) Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101:758-765
67. Bayry J, Lacroix-Desmazes S, Delignat S, Mouthon L, Weill B, Kazatchkine MD, Kaveri SV (2003) Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. Arthritis Rheum 48:3497-3502
68. Shioji K, Kishimoto C, Sasayama S (2001) Fc receptor-mediated inhibitory effect of immunoglobulin therapy on autoimmune giant cell myocarditis: concomitant suppression of the expression of dendritic cells. Circ Res 89:540-546
69. Siragam V, Crow AR, Brinc D, Song S, Freedman J, Lazarus AH (2006) Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 12:688-692
70. Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE (1984) Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 2:765-768
71. Rossi F, Sultan Y, Kazatchkine MD (1988) Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin Exp Immunol 74:311-316
72. Rossi F, Jayne DR, Lockwood CM, Kazatchkine MD (1991) Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol 83:298-303
73. Abedi MR, Hammarstrom L, Broome U, Angelin B, Smith CI, Christensson B (1996) Reduction in serum levels of antimitochondrial (M2) antibodies following immunoglobulin therapy in severe combined immunodeficient (SCID) mice reconstituted with lymphocytes from patients with primary biliary cirrhosis (PBC). Clin Exp Immunol 105:266-273
74. Vassilev T, Yamamoto M, Aissaoui A, Bonnin E, Berrih-Aknin S, Kazatchkine MD, Kaveri SV (1999) Normal human immunoglobulin suppresses experimental myasthenia gravis in SCID mice. Eur J Immunol 29:2436-2442
75. de Grandmont MJ, Racine C, Roy A, Lemieux R, Neron S (2003) Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgG. Blood 101:3065-3073
76. Bayry J, Fournier EM, Maddur MS, Vani J, Wootla B, Siberil S, Dimitrov JD, Lacroix- Desmazes S, Berdah M, Crabol Y, Oksenhendler E, Levy Y, Mouthon L, Sautes- Fridman C, Hermine O, Kaveri SV (2011) Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun 36:9-15
77. Rigal D, Vermot-Desroches C, Heitz S, Bernaud J, Alfonsi F, Monier JC (1994) Effects of intravenous immunoglobulins (IVIG) on peripheral blood B, NK, and T cell subpopulations in women with recurrent spontaneous abortions: specific effects on LFA-1 and CD56 molecules. Clin Immunol Immunopathol 71:309-314
78. Tha-In T, Metselaar HJ, Tilanus HW, Boor PP, Mancham S, Kuipers EJ, de Man RA, Kwekkeboom J (2006) Superior immunomodulatory effects of intravenous immunoglobulins on human T-cells and dendritic cells: comparison to calcineurin inhibitors. Transplantation 81:1725-1734
79. Pashov A, Dubey C, Kaveri SV, Lectard B, Huang YM, Kazatchkine MD, Bellon B (1998) Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein. Eur J Immunol 28:1823-1831
80. Saoudi A, Hurez V, de Kozak Y, Kuhn J, Kaveri SV, Kazatchkine MD, Druet P, Bellon B (1993) Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int Immunol 5:1559-1567
81. Achiron A, Mor F, Margalit R, Cohen IR, Lider O, Miron S (2000) Suppression of experimental autoimmune encephalomyelitis by intravenously administered polyclonal immunoglobulins. J Autoimmun 15:323-330
82. Nicoletti A, Kaveri S, Caligiuri G, Bariety J, Hansson GK (1998) Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest 102:910-918
83. Shirin H, Bruck R, Aeed H, Hershkoviz R, Lider O, Kenet G, Avni Y, Halpern Z (1997) Effects of intravenous immunoglobulins on T-cell mediated, concanavalin A-induced hepatitis in mice. Liver 17:275-280
84. Kessel A, Ammuri H, Peri R, Pavlotzky ER, Blank M, Shoenfeld Y, Toubi E (2007) Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 179:5571-5575
85. Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, Delignat S, Elluru S, Bayry J, Lacroix-Desmazes S, Cohen JL, Salomon BL, Kazatchkine MD, Kaveri SV, Misra N (2008) Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111:715-722
86. Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497
87. Klinman NR, Segal GP, Gerhard W, Braciale T, Levy R (1977) Obtaining homogeneous antibody of desired specificity from fragment cultures. In: Haber E, Krause RM (eds) Antibodies in human diagnosis and therapy. Raven, New York, pp 225-236
88. Miller RA, Maloney DG, Warnke R, Levy R (1982) Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 306:517-522
89. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A 81:6851-6855
90. Boulianne GL, Hozumi N, Shulman MJ (1984) Production of functional chimaeric mouse/human antibody. Nature 312:643-646
91. den Broeder A, van de Putte L, Rau R, Schattenkirchner M, Van Riel P, Sander O, Binder C, Fenner H, Bankmann Y, Velagapudi R, Kempeni J, Kupper H (2002) A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 29:2288-2298
92. Rau R (2002) Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis 61(Suppl 2):ii70-ii73
93. Onrust SV, Lamb HM (1998) Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs 10:397-422
94. Cuchacovich M, Soto L, Edwardes M, Gutierrez M, Llanos C, Pacheco D, Sabugo F, Alamo M, Fuentealba C, Villanueva L, Gatica H, Schiattino I, Salazaro L, Catalan D, Valenzuela O, Salazar-Onfray F, Aguillon JC (2006) Tumour necrosis factor (TNF)alpha- 308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand J Rheumatol 35: 435-440
95. Danese S, Sans M, Scaldaferri F, Sgambato A, Rutella S, Cittadini A, Pique JM, Panes J, Katz JA, Gasbarrini A, Fiocchi C (2006) TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol 176:2617-2624
96. Kirman I, Whelan RL, Nielsen OH (2004) Infliximab: mechanism of action beyond TNF-alpha neutralization in inflammatory bowel disease. Eur J Gastroenterol Hepatol 16:639-641
97. Ames SA, Gleeson CD, Kirkpatrick P (2004) Omalizumab. Nat Rev Drug Discov 3:199-200
98. Bang LM, Plosker GL (2004) Spotlight on omalizumab in allergic asthma. BioDrugs 18:415-418
99. Hennemann A (2004) Omalizumab. A monoclonal antibody against IgE. Med Monatsschr Pharm 27:404-407
100. Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Cioppa GD (2004) Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 34:632-638
101. Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebocontrolled, phase III trial. Lancet 374: 210-221
102. Oldfield V, Plosker GL (2009) Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. BioDrugs 23:125-135
103. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four- week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60:976-986
104. Faulds D, Sorkin EM (1994) Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease. Drugs 48:583-598
105. Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW (2003) Benefits and risks of Abciximab use in primary angioplasty for acute myocardial infarction: the controlled Abciximab and device investigation to lower late angioplasty complications (CADILLAC) trial. Circulation 108: 1316-1323
106. Schror K, Weber AA (2003) Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thrombolysis 15:71-80
107. Weber AA, Schror K (2001) Differential inhibition of adenosine diphosphate- versus thrombin receptor-activating peptidestimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics. Blood 98:1619-1621
108. Walsh GM (2009) Canakinumab for the treatment of cryopyrin-associated periodic syndromes. Drugs Today (Barc) 45:731-735
109. Lachmann HJ, Kone-Paut I, Kuemmerle- Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins PN (2009) Use of canakinumab in the cryopyrin- associated periodic syndrome. N Engl J Med 360:2416-2425
110. Church LD, McDermott MF (2009) Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther 11:81-89
111. Baumgart DC, Sandborn WJ (2007) Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369:1641-1657
112. Stefanelli T, Malesci A, Repici A, Vetrano S, Danese S (2008) New insights into inflammatory bowel disease pathophysiology: paving the way for novel therapeutic targets. Curr Drug Targets 9:413-418
113. Lalande JD, Behr MA (2010) Mycobacteria in Crohn's disease: how innate immune defi- ciency may result in chronic inflammation. Expert Rev Clin Immunol 6:633-641
114. Brynskov J, Foegh P, Pedersen G, Ellervik C, Kirkegaard T, Bingham A, Saermark T (2002) Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut 51:37-43
115. Baker DE (2008) Certolizumab pegol: a polyethylene glycolated Fab' fragment of humanized anti-tumor necrosis factor alpha monoclonal antibody for the treatment of Crohn's disease. Rev Gastroenterol Disord 8:240-253
116. Patel VK, Ghosh S (2008) Certolizumab pegol in Crohn's disease. Drugs Today (Barc) 44:837-844
117. Sandborn WJ (2008) Certolizumab pegol for moderate-to-severe Crohn's disease. Gastroenterol Hepatol (NY) 4:467-468
118. Danese S, Mocciaro F, Guidi L, Scribano ML, Comberlato M, Annese V, Colombo E, Stefanelli T, Marzo M, Vangeli M, Pulitano R, Manca A, Armuzzi A, Malesci A, Prantera C, Cottone M (2008) Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a reallife multicenter experience of compassionate use. Inflamm Bowel Dis 14:1168-1170
119. Schreiber S (2005) The complicated path to true causes of disease: role of nuclear factor kappaB in inflammatory bowel disease. Gut 54:444-445
120. Rosenfeld PJ, Rich RM, Lalwani GA (2006) Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 19:361-372
121. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431
122. Narayanan R, Kuppermann BD, Jones C, Kirkpatrick P (2006) Ranibizumab. Nat Rev Drug Discov 5:815-816
123. Dugel PU (2006) Ranibizumab treatment of patients with ocular diseases. Int Ophthalmol Clin 46:131-140
124. Subramanian ML, Abedi G, Ness S, Ahmed E, Fenberg M, Daly MK, Houranieh A, Feinberg EB (2010) Bevacizumab vs. ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double- masked randomised clinical trial. Eye (Lond) 24: 1708-1715
125. Wootla B, Eriguchi M, Rodriguez M (2012) Is multiple sclerosis an autoimmune disease? Autoimmune Dis 2012:969657
126. Bartt RE (2006) Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy. Curr Opin Neurol 19:341-349
127. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899-910
128. Ramos-Cejudo J, Oreja-Guevara C, Stark Aroeira L, Rodriguez de Antonio L, Chamorro B, Diez-Tejedor E (2011) Treatment with natalizumab in relapsingremitting multiple sclerosis patients induces changes in inflammatory mechanism. J Clin Immunol 31:623-631
129. Rice GP, Hartung HP, Calabresi PA (2005) Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 64:1336-1342
130. Linda H, von Heijne A, Major EO, Ryschkewitsch C, Berg J, Olsson T, Martin C (2009) Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 361:1081-1087
131. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366:1870-1880
132. Hillmen P, Muus P, Duhrsen U, Risitano AM, Schubert J, Luzzatto L, Schrezenmeier H, Szer J, Brodsky RA, Hill A, Socie G, Bessler M, Rollins SA, Bell L, Rother RP, Young NS (2007) Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 110:4123-4128
133. Parker CJ, Kar S, Kirkpatrick P (2007) Eculizumab. Nat Rev Drug Discov 6:515-516
134. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L (2007) Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25:1256-1264
135. Zareba KM (2007) Eculizumab: a novel therapy for paroxysmal nocturnal hemoglobinuria. Drugs Today (Barc) 43:539-546
136. Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, Roth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355:1233-1243
137. Weinberg JM, Saini R, Tutrone WD (2002) Biologic therapy for psoriasis-the first wave: infliximab, etanercept, efalizumab, and alefacept. J Drugs Dermatol 1:303-310
138. Dedrick RL, Walicke P, Garovoy M (2002) Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody. Transpl Immunol 9:181-186
139. News (2002) Efalizumab. Anti-CD11a monoclonal antibody-Genentech/Xoma, HU 1124, hu1124, xanelim. Drugs R&D 3:40-43
140. Berger JR, Houff SA, Major EO (2009) Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs 1:583-589
141. Agarwal SK (2011) Biologic agents in rheumatoid arthritis: an update for managed care professionals. J Manag Care Pharm 17:S14-S18
142. Nakou M, Katsikas G, Sidiropoulos P, Bertsias G, Papadimitraki E, Raptopoulou A, Koutala H, Papadaki HA, Kritikos H, Boumpas DT (2009) Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther 11:R131
143. Kishimoto T (2006) Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 8(Suppl 2):S2
144. Madhok R, Crilly A, Watson J, Capell HA (1993) Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 52:232-234
145. Yoshizaki K, Nishimoto N, Mihara M, Kishimoto T (1998) Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin Immunopathol 20:247-259
146. Dennis GJ (2012) Belimumab: a BLySspecific inhibitor for the treatment of systemic lupus erythematosus. Clin Pharmacol Ther 91:143-149
147. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63:3918-3930
148. Sanz I, Yasothan U, Kirkpatrick P (2011) Belimumab. Nat Rev Drug Discov 10: 335-336
149. Macris MP, Frazier OH, Lammermeier D, Radovancevic B, Duncan JM (1989) Clinical experience with Muromonab-CD3 monoclonal antibody (OKT3) in heart transplantation. J Heart Transplant 8:281-287
150. Todd PA, Brogden RN (1989) Muromonab CD3. A review of its pharmacology and therapeutic potential. Drugs 37:871-899
151. Emmons C, Hunsicker LG (1987) Muromonab-CD3 (Orthoclone OKT3): the first monoclonal antibody approved for therapeutic use. Iowa Med 77:78-82
152. Midtvedt K, Fauchald P, Lien B, Hartmann A, Albrechtsen D, Bjerkely BL, Leivestad T, Brekke IB (2003) Individualized T cell monitored administration of ATG versus OKT3 in steroid-resistant kidney graft rejection. Clin Transplant 17:69-74
153. Kovarik J, Breidenbach T, Gerbeau C, Korn A, Schmidt AG, Nashan B (1998) Disposition and immunodynamics of basiliximab in liver allograft recipients. Clin Pharmacol Ther 64: 66-72
154. News (1998) Basiliximab approved for use in renal transplant patients. Am J Health Syst Pharm 55:1444-1445
155. Vincenti F, Nashan B, Light S (1998) Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups. Transplant Proc 30:2155-2158
156. Abramowicz D (1998) Daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 338:1700-1701
157. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J (1998) Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 338:161-165
158. Treish IM (2000) Targeting leukemia cells with gemtuzumab ozogamicin. Cancer Pract 8:254-257
159. Niculescu-Duvaz I (2000) Technology evaluation: gemtuzumab ozogamicin. Celltech Group. Curr Opin Mol Ther 2:691-696
160. de Vetten MP, Jansen JH, van der Reijden BA, Berger MS, Zijlmans JM, Lowenberg B (2000) Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA- 676). Br J Haematol 111:277-279
161. Naito K, Takeshita A, Shigeno K, Nakamura S, Fujisawa S, Shinjo K, Yoshida H, Ohnishi K, Mori M, Terakawa S, Ohno R (2000) Calicheamicin-conjugated humanized anti- CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on
162. News (2000) Gemtuzumab for relapsed acute myeloid leukemia. Med Lett Drugs Ther 42:67-68
163. Communication (1998) Molecule of the month: trastuzumab. Drug News Perspect 11:305
164. Communication (1998) Trastuzumab and capecitabine for metastatic breast cancer. Med Lett Drugs Ther 40:106-108
165. Mir O, Berveiller P, Pons G (2007) Trastuzumab-mechanism of action and use. N Engl J Med 357:1664-1665, author reply 1665-1666
166. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG (2007) Trastuzumab- mechanism of action and use. N Engl J Med 357:1664, author reply 1665-1666
167. Hudis CA (2007) Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357:39-51
168. Valabrega G, Montemurro F, Aglietta M (2007) Trastuzumab: mechanism of action, resistance and future perspectives in HER2- overexpressing breast cancer. Ann Oncol 18:977-984
169. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA (1999) Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26:60-70
170. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712
171. Ferrajoli A, O'Brien S, Keating MJ (2001) Alemtuzumab: a novel monoclonal antibody. Expert Opin Biol Ther 1:1059-1065
172. Smith JA (2001) Alemtuzumab: a new option for refractory chronic lymphocytic leukemia? Cancer Pract 9:211-213
173. Castillo J, Milani C, Mendez-Allwood D (2009) Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opin Investig Drugs 18:491-500
174. Traynor K (2009) Ofatumumab approved for advanced CLL. Am J Health Syst Pharm 66:2062
175. Zhang B (2009) Ofatumumab. MAbs 1: 326-331
176. Du J, Yang H, Guo Y, Ding J (2009) Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol 46:2419-2423
177. Mone AP, Cheney C, Banks AL, Tridandapani S, Mehter N, Guster S, Lin T, Eisenbeis CF, Young DC, Byrd JC (2006) Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia 20:272-279
178. Herbst RS (2004) Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59:21-26
179. Chu E (2006) Panitumumab: a new anti- EGFR antibody for the treatment of advanced colorectal cancer. Clin Colorectal Cancer 6:13
180. Hoy SM, Wagstaff AJ (2006) Panitumumab: in the treatment of metastatic colorectal cancer. Drugs 66:2005-2014, discussion 2015-2006
181. Saltz L, Easley C, Kirkpatrick P (2006) Panitumumab. Nat Rev Drug Discov 5: 987-988
182. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391-400
183. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK (2004) Direct evidence that the VEGFspecific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147
184. Fanale MA, Forero-Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, Han TH, Sievers EL, Bartlett NL (2012) A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30- positive hematologic malignancies. Clin Cancer Res 18:248-255
185. Foyil KV, Bartlett NL (2011) Brentuximab vedotin for the treatment of CD30+ lymphomas. Immunotherapy 3:475-485
186. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195
187. Anderson DR, Grillo-Lopez A, Varns C, Chambers KS, Hanna N (1997) Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 25:705-708
188. Gibson AD (2002) Updated results of a Phase III trial comparing ibritumomab tiuxetan with rituximab in previously treated patients with non-Hodgkin's lymphoma. Clin Lymphoma 3:87-89
189. Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-Lopez AJ, White CA (2002) Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99:4336-4342
190. Zelenetz AD (2003) A clinical and scientific overview of tositumomab and iodine I 131 tositumomab. Semin Oncol 30:22-30
191. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, Fisher RI (2003) A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 102:1606-1612
192. News (2003) Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131) I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab. BioDrugs 17:290-295
193. News (2003) Iodine-131 tositumomab (bexxar) for treatment of lymphoma. Med Lett Drugs Ther 45:86-87
194. Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ, Weber JS (2011) A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapynaive patients with advanced melanoma. Invest New Drugs 29:489-498
195. Robert C, Thomas L, Bondarenko I, O'Day S, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526
196. Robert C, Ghiringhelli F (2009) What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist 14:848-861
197. Baron R, Ferrari S, Russell RG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48: 677-692
198. Iqbal J, Sun L, Zaidi M (2010) Denosumab for the treatment of osteoporosis. Curr Osteoporos Rep 8:163-167
199. Lewiecki EM (2010) Denosumab-an emerging treatment for postmenopausal osteoporosis. Expert Opin Biol Ther 10:467-476
200. Rizzoli R, Yasothan U, Kirkpatrick P (2010) Denosumab. Nat Rev Drug Discov 9: 591-592
201. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821-831
202. Lei S, Shiying Y (2012) Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and meta-analysis. Am J Clin Oncol 2012 Oct 8. [Epub ahead of print]
203. Guideline P (1998) Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Pediatrics 102:1211-1216
204. Trial C (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 102:531-537
205. Shadman KA, Wald ER (2011) A review of palivizumab and emerging therapies for respiratory syncytial virus. Expert Opin Biol Ther 11:1455-1467
206. Warrington AE, Asakura K, Bieber AJ, Ciric B, Van Keulen V, Kaveri SV, Kyle RA, Pease LR, Rodriguez M (2000) Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Natl Acad Sci U S A 97: 6820-6825
207. Mitsunaga Y, Ciric B, Van Keulen V, Warrington AE, Paz Soldan M, Bieber AJ, Rodriguez M, Pease LR (2002) Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease. FASEB J 16:1325-1327
208. Warrington AE, Bieber AJ, Ciric B, Pease LR, Van Keulen V, Rodriguez M (2007) A recombinant human IgM promotes myelin repair after a single, very low dose. J Neurosci Res 85:967-976
209. Warrington AE, Bieber AJ, Van Keulen V, Ciric B, Pease LR, Rodriguez M (2004) Neuron-binding human monoclonal antibodies support central nervous system neurite extension. J Neuropathol Exp Neurol 63: 461-473
210. Van Keulen VP, Ciric B, Radhakrishnan S, Heckman KL, Mitsunaga Y, Iijima K, Kita H, Rodriguez M, Pease LR (2006) Immunomodulation using the recombinant monoclonal human B7-DC cross-linking antibody rHIgM12. Clin Exp Immunol 143: 314-321
211. Xu X, Warrington AE, Wright BR, Bieber AJ, Van Keulen V, Pease LR, Rodriguez M (2011) A human IgM signals axon outgrowth: coupling lipid raft to microtubules. J Neurochem 119:100-112
212. Denic A, Macura SI, Warrington AE, Pirko I, Grossardt BR, Pease LR, Rodriguez M (2011) A single dose of neuron-binding human monoclonal antibody improves spontaneous activity in a murine model of demyelination. PLoS One 6:e26001
213. Watzlawik J, Holicky E, Edberg DD, Marks DL, Warrington AE, Wright BR, Pagano RE, Rodriguez M (2010) Human remyelination promoting antibody inhibits apoptotic signaling and differentiation through Lyn kinase in primary rat oligodendrocytes. Glia 58:1782-1793
214. Wright BR, Warrington AE, Edberg DD, Rodriguez M (2009) Cellular mechanisms of central nervous system repair by natural autoreactive monoclonal antibodies. Arch Neurol 66:1456-1459
215. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC (2005) Monoclonal antibody successes in the clinic. Nat Biotechnol 23:1073-1078
216. Rieben R, Roos A, Muizert Y, Tinguely C, Gerritsen AF, Daha MR (1999) Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. Blood 93:942-951
217. Walpen AJ, Laumonier T, Aebi C, Mohacsi PJ, Rieben R (2004) Immunoglobulin M-enriched intravenous immunoglobulin inhibits classical pathway complement activation, but not bactericidal activity of human serum. Xenotransplantation 11:141-148
218. Stehr SN, Knels L, Weissflog C, Schober J, Haufe D, Lupp A, Koch T, Heller AR (2008) Effects of IGM-enriched solution on polymorphonuclear neutrophil function, bacterial clearance, and lung histology in endotoxemia. Shock 29:167-172
219. Bieber AJ, Warrington A, Asakura K, Ciric B, Kaveri SV, Pease LR, Rodriguez M (2002) Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice. Glia 37:241-249
220. Hurez V, Kazatchkine MD, Vassilev T, Ramanathan S, Pashov A, Basuyaux B, de Kozak Y, Bellon B, Kaveri SV (1997) Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease. Blood 90:4004-4013
221. Varambally S, Bar-Dayan Y, Bayry J, Lacroix- Desmazes S, Horn M, Sorel M, Bar-Dayan Y, Ruberti G, Kazatchkine MD, Kaveri SV (2004) Natural human polyreactive IgM induce apoptosis of lymphoid cell lines and human peripheral blood mononuclear cells. Int Immunol 16:517-524
222. Vassilev T, Mihaylova N, Voynova E, Nikolova M, Kazatchkine M, Kaveri S (2006) IgMenriched human intravenous immunoglobulin suppresses T lymphocyte functions in vitro and delays the activation of T lymphocytes in hu- SCID mice. Clin Exp Immunol 145:108-115
223. Bregenholt S, Jensen A, Lantto J, Hyldig S, Haurum JS (2006) Recombinant human polyclonal antibodies: a new class of therapeutic antibodies against viral infections. Curr Pharm Des 12:2007-2015
224. Frandsen TP, Naested H, Rasmussen SK, Hauptig P, Wiberg FC, Rasmussen LK, Jensen AM, Persson P, Wiken M, Engstrom A, Jiang Y, Thorpe SJ, Forberg C, Tolstrup AB (2011) Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use. Biotechnol Bioeng 108:2171-2181
225. Koefoed K, Steinaa L, Soderberg JN, Kjaer I, Jacobsen HJ, Meijer PJ, Haurum JS, Jensen A, Kragh M, Andersen PS, Pedersen MW (2011) Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs 3:584-595